EA201990115A1 - Oligomers for skipping the exon in muscular dystrophy - Google Patents

Oligomers for skipping the exon in muscular dystrophy

Info

Publication number
EA201990115A1
EA201990115A1 EA201990115A EA201990115A EA201990115A1 EA 201990115 A1 EA201990115 A1 EA 201990115A1 EA 201990115 A EA201990115 A EA 201990115A EA 201990115 A EA201990115 A EA 201990115A EA 201990115 A1 EA201990115 A1 EA 201990115A1
Authority
EA
Eurasian Patent Office
Prior art keywords
skipping
exon
oligomers
muscular dystrophy
target site
Prior art date
Application number
EA201990115A
Other languages
Russian (ru)
Inventor
Дайан Элизабет Франк
Ричард К. Бестуик
Original Assignee
Сарепта Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сарепта Терапьютикс, Инк. filed Critical Сарепта Терапьютикс, Инк.
Priority claimed from PCT/US2017/040017 external-priority patent/WO2018005805A1/en
Publication of EA201990115A1 publication Critical patent/EA201990115A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Abstract

Описаны антисмысловые олигомеры, комплементарные выбранному целевому сайту в гене дистрофина человека, для индукции пропуска экзона 45.Antisense oligomers complementary to the selected target site in the human dystrophin gene are described to induce exon 45 skipping.

EA201990115A 2016-06-30 2017-06-29 Oligomers for skipping the exon in muscular dystrophy EA201990115A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662356923P 2016-06-30 2016-06-30
PCT/US2017/040017 WO2018005805A1 (en) 2016-06-30 2017-06-29 Exon skipping oligomers for muscular dystrophy

Publications (1)

Publication Number Publication Date
EA201990115A1 true EA201990115A1 (en) 2019-05-31

Family

ID=63962974

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990115A EA201990115A1 (en) 2016-06-30 2017-06-29 Oligomers for skipping the exon in muscular dystrophy

Country Status (2)

Country Link
AR (1) AR108914A1 (en)
EA (1) EA201990115A1 (en)

Also Published As

Publication number Publication date
AR108914A1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
MX2019006882A (en) Exon skipping oligomer conjugates for muscular dystrophy.
MX2019006879A (en) Exon skipping oligomer conjugates for muscular dystrophy.
SA519402143B1 (en) Exon Skipping Oligomer Conjugates for Muscular Dystrophy
EA201991450A1 (en) OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY
CY1121876T1 (en) EXON BYPASS COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DYSTROPHY
MX2018016052A (en) Exon skipping oligomers for muscular dystrophy.
EA202090946A2 (en) COMPOSITIONS PROVIDING EXONE LEAKING FOR THE TREATMENT OF MUSCLE DYSTROPHY
DK3636764T3 (en) 3 'UTR SEQUENCES FOR RNA STABILIZATION
IL247663B (en) Antisense oligomers for skipping exon 51 in the human dystrophin gene
IL258471A (en) 11,13-modified saxitoxins for the treatment of pain
EP3464313A4 (en) 5'-cyclo-phosphonate modified nucleotides
MY185390A (en) Antisense nucleic acids
BR112018005409A2 (en) glycodirectional therapy.
EA202092772A1 (en) OLIGOMER CONJUGATES FOR EXONE PASSING IN MUSCLE DYSTROPHY
DK3294756T3 (en) Retroviral particle, comprising at least two different encapsulated, non-viral RNAs
EA201990115A1 (en) Oligomers for skipping the exon in muscular dystrophy
EA201991449A1 (en) OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY
EA201991458A1 (en) OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY
ITUB20153493A1 (en) EQUIPMENT FOR STUDIES APPLICATION.
Einaudi Experience
Center D SITE
EP4219717A3 (en) Exon skipping oligomers for muscular dystrophy
میران زاده et al. بررسی کارایی برکه های تثبیت تلفیقی در تصفیه فاضلاب شهری
MARTINEZ-CONDE et al. Victorian Theatrics
Makin Schizophrenia's Genetic Roots